The Truth About 340B – and Why Drug Companies Want It Weakened

0
94

By Amelia Hamilton

As healthcare costs rise for small businesses, some are pointing the finger at drug discount program 340B. While it might seem an easy target on which to pin the blame, the reality is far more complicated.

For more than thirty years, 340B has been helping Americans access medications they might otherwise be unable to afford while providing a lifeline for health care providers who serve a large proportion of poorer patients, and many of whose finances are therefore shaky. The program is the result of a bipartisan effort that granted pharmaceutical companies access to Medicare Part B and Medicaid markets in exchange for providing drugs at a discount to 340B hospitals, health centers, and clinics. That gave those drugmakers access to approximately half of the U.S. population — and the taxpayer money that funds their healthcare — and gave those…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here